PRESCRIBER'S NIGHTMARE by Shamasundar, C.
Indian J. Psychiat. 1992, 34(4),397-398 
LETTER TO THE EDITOR 
PRESCRIBER'S NIGHTMARE 
Dear Sir, 
I like to express my concern about the not to healthy state of affairs in respect of psycho-
pharmacological drugs in our country. 
The final test of my drug's usefulness is how consistently it exhibits its virtues and limitations 
in clinical practice over a period of time. This requires its use in clinical practice on the strength 
of its performance in controlled clinical trials. But, there are five to twelve proprietary preperations 
in our country for each of the common psychopharmacogical drugs to choose from. 
23 common drugs are available under 157 proprietary names. 5 of them have 12 or more 
preperations each (viz: Trifiuperazine), and 5 have five preperation each (viz: Doxepin, Pimozide). 
The precriber's first problem is : On what basis to make the choice? On the basis of the 
established name of the comapny? On the basis of the retail price of the drug? In the recent past, 
the drug were required to be prescribed by their pharmacological name, with the prescribing doctor 
having the option to mention the company's name alongside. For many reasons, this practice did 
not catch on. One of the principle reason was the patient's confusion, anxiety and doubt about the 
brand-name dispensed by the chemist, the patient running back to the doctor for specific advise. 
Consequently, the old practice of prescribing by brand-name has crept back. 
The prescriber's next problem, is the confusing nomenclature of the various drugs by 
different companies. The notorious illegibility of the doctor's handwrilting adds a dangerous 
dimensions to this problem. The confusion in nomenclature is in the similar sounding names, and 
even worse, similar pattern of spelling. For example: 
(1) Relicalm (Trifiuperazine) (2) Seradol (Haloperidol) 
Relinase (Haloperidol) Seridac (Mianserin) 
Relitil (Chloropromazine) Serodep (Trazadone) 
Restamine (Imipramine) Serotena (Amitriptyline) 
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(3) Elcion (Diazepam) (4) Prazcp (Imipramine) 
Elewal (Doxepinc) Prodep (Fluoxetine) 
Eliwel (Amitriptyline) Prolinate (Flufenazine deconoate) 
Emetil (Chlorpromazine) Prothiaden (Dothiepin) 
(5) Melozine (Trioridazine) (6) Depidol (Haloperidol) 
Mezatil (Chloropromazine) Depryl (Trazadone) 
Mazetol (Carbamezapine) Depsol (Imipramine) 
(7) Anxit (Alprazolam) (8) Flumap (Penfluridol) 
Anxol (Diazepam) Flunil (Fluoxetine) 
Anxipar (Buspiron) Fluraz (Flurazepam) 
Anxipax (Alprazolam) 
I do not know for cetain if mis-dispensing takes place, but, I very much suspect that it does 
take place. Here, the magnitude of such a possibility is not important, but the very possibility 
demands utmost concern. 
I suggest one or many of the following remedial measures : 
(1) In manual consultation with each other, the pharmaceutical companies (a) restrict the 
number of each one of their psychopharmacological drugs to 3 or 4; (b) re-name their products in 
such a way that in spelling and pronounciation, the names are distinct from other; (c) re-organise 
their marketing such that in any state, a psycho-pharmacological drug is represented by not more 
than three companies. 
(2) The Government directs/monitors the pharmaceutical companies to pursue the above 
or even better policies. 
I believe that this issue warrants the urgent attention of the Indian Psychiatric Society, so 
that it may take-up the matter with both the pharmaceutical companies and the Government. 
Yours sincerely, 
C. SHAMASUNDAR
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